Drug Profile

Anti-CD38/CD3 bispecific antibody - Sorrento Therapeutics

Alternative Names: Anti-CD38/CD3 T-cell-redirecting bispecific antibody - Sorrento Therapeutics

Latest Information Update: 28 Jan 2024

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Sorrento Therapeutics
Class Antineoplastics; Bispecific antibodies; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; T lymphocyte stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

No development reported Lymphoma; Multiple myeloma

Most Recent Events

28 Jan 2024 No recent reports of development identified for preclinical development in Lymphoma in USA (Parenteral)
28 Jan 2024 No recent reports of development identified for preclinical development in Multiple-myeloma in USA (Parenteral)
19 Dec 2019 Sorrento Therapeutics announces intention to file IND application in second half of 2020

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com